It's Maybe the Potential Partner(s) or Buyer of Nupathe Who Have Committed These Short Sales All Along
For one and only one reason: it (they) don't want to pay $20 or $10 a share. Since path is a easily manipulated small biotech company, these manipulators may not be required to report to SEC for the shares involved in manipulation are less than 5% of the total shares.
Just a possibility for anyone who has the means to do some investigation. But I hope it is just a one or two time events, and the price will be appreciated steadily starting from Monday!
You are living in la la land if you actually think Fortune 500 pharma companies would illegally short a potential target and their CEOs would risk going to jail to save what is a "few bucks" to them. No, it's not possible